Top Markets
Coin of the day
Nuformix plc Nuformix plc

Nuformix plc

NFX
Clasificación en acciones #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Precio por acción
$0.00244926
Capitalización bursátil
$51.67K
Cambio (1 día)
5.88%
Cambio (1 año)
110.15%
País
GB
Comercio Nuformix plc (NFX)

Categoría

Ganancias de Nuformix plc (NFX)
Ganancias en Sep 2025 TTM: $-5.28M
Secondo gli ultimi rapporti finanziari di Nuformix plc, gli utili attuali della società sono $-5.28M. Nel 2024, la società ha registrato un utile di $-4.88M, una disminución en comparación con agli utili del 2023, che erano di $-754.56K. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Nuformix plc desde 2014 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-5.28M 494.63%
2025 $-888.01K -81.80%
2024 $-4.88M 546.72%
2023 $-754.56K -54.82%
2022 $-1.67M -11.94%
2021 $-1.90M 64.37%
2020 $-1.15M -51.92%
2019 $-2.40M -12.87%
2018 $-2.75M 220.48%
2017 $-859.40K 70.68%
2016 $-503.51K -206.04%
2014 $474.83K 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$20.46B -387,521.89%
DK
$4.64B -88,033.93%
US
$5.23B -99,160.13%
US
$2.14B -40,584.12%
BE
$1.61B -30,671.66%
AU